Innate Pharma SA Total Long Term Liabilities 2012-2023 | IPHYF

Innate Pharma SA total long term liabilities from 2012 to 2023. Total long term liabilities can be defined as the sum of all non-current liabilities.

Innate Pharma SA Total Long Term Liabilities 2012-2023 | IPHYF

Innate Pharma SA total long term liabilities from 2012 to 2023. Total long term liabilities can be defined as the sum of all non-current liabilities.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$77.1B
Chugai Pharmaceutical (CHGCY)$71.1B
Takeda Pharmaceutical (TAK)$42.6B
Sandoz Group AG (SDZNY)$21B
Merck (MKKGY)$19.6B
Astellas Pharma (ALPMY)$17.5B
Summit Therapeutics (SMMT)$15.9B
United Therapeutics (UTHR)$15.7B
Neurocrine Biosciences (NBIX)$15.4B
Shionogi (SGIOY)$13B
Orion OYJ (ORINY)$7.7B
Madrigal Pharmaceuticals (MDGL)$7.3B
Corcept Therapeutics (CORT)$7B
Stevanato Group S.p.A (STVN)$6.8B
Hikma Pharmaceuticals Plc (HKMPF)$5.9B
Ionis Pharmaceuticals (IONS)$5B
Grifols, S.A (GRFS)$4.7B
Ono Pharmaceutical (OPHLF)$4.3B
Crinetics Pharmaceuticals (CRNX)$3.7B
Recursion Pharmaceuticals (RXRX)$2.8B
Catalyst Pharmaceuticals (CPRX)$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
Centessa Pharmaceuticals (CNTA)$2.2B
Soleno Therapeutics (SLNO)$2.2B
NewAmsterdam Pharma (NAMS)$2.1B
Hypermarcas (HYPMY)$2B
Indivior (INDV)$1.6B
BioCryst Pharmaceuticals (BCRX)$1.6B
Evotec AG (EVO)$1.6B
Dyne Therapeutics (DYN)$1.4B